NCT03517488 (DUET-2) is a Phase 1 clinical trial of XmAb20717 in Melanoma, sponsored by Xencor, Inc..

Who is sponsoring NCT03517488?

NCT03517488 is sponsored by Xencor, Inc..

What drugs are being tested in NCT03517488?

Interventions in NCT03517488: XmAb20717.

What condition does NCT03517488 study?

NCT03517488 studies Melanoma, Breast Carcinoma, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Colorectal Carcinoma, Non-small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Endometrial Carcinoma, Mesothelioma, Neuroendocrine Carcinoma, Cervical Cancer, Small Cell Lung Carcinoma, Squamous Cell Carcinoma of the Anus, Castration-Resistant Prostate Carcinoma, Nasopharyngeal Carcinoma, Cholangiocarcinoma, Basal Cell Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Thymoma, Thymic Carcinoma, Squamous Cell Carcinoma of the Penis, Vulvar Carcinoma, Solid Tumors With Published Evidence of Anti-tumor Activity With Anti-PD1/PDL1 and/or Anti-CTLA4-directed Therapy, Malignant Adnexal Neoplasms, Non-squamous Cell Salivary Gland Carcinoma.

Is NCT03517488 still recruiting?

NCT03517488 is currently completed. Last updated 1 December 2022.

Last reviewed 2022-12-01 · How we verify

NCT03517488: DUET-2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors

Completed Phase 1 Last updated 1 December 2022

What this trial tests

Phase 1 trial testing XmAb20717 in Melanoma in 150 participants. Completed in 6 September 2022.

Timeline

10 July 2018

Primary endpoint
1 June 2022

6 September 2022

Quick facts

Lead sponsor	Xencor, Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	150
Start date	10 July 2018
Primary completion	1 June 2022
Estimated completion	6 September 2022
Sites	17 locations across United States

Drugs / interventions tested

XmAb20717 — full drug profile →

Conditions studied

Melanoma — all drugs for Melanoma →
Breast Carcinoma — all drugs for Breast Carcinoma →
Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →
Urothelial Carcinoma — all drugs for Urothelial Carcinoma →

Sponsor

Xencor, Inc. — full company profile →

Who can join

18 and older, any sex, with Melanoma or Breast Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb20717, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb20717 in subjects with selected advanced solid tumors.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Recent advances in therapeutic strategies for triple-negative breast cancer.
Li Y, Zhang H, Merkher Y, Chen L, et al · · 2022 · cited 643× · PMID 36038913 · DOI 10.1186/s13045-022-01341-0
Emerging new therapeutic antibody derivatives for cancer treatment.
Jin S, Sun Y, Liang X, Gu X, et al · · 2022 · cited 304× · PMID 35132063 · DOI 10.1038/s41392-021-00868-x
Development of Immunotherapy Combination Strategies in Cancer.
Yap TA, Parkes EE, Peng W, Moyers JT, et al · · 2021 · cited 260× · PMID 33811048 · DOI 10.1158/2159-8290.cd-20-1209
Bispecific Antibodies: From Research to Clinical Application.
Ma J, Mo Y, Tang M, Shen J, et al · · 2021 · cited 199× · PMID 34025638 · DOI 10.3389/fimmu.2021.626616
Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics.
Runcie K, Budman DR, John V, Seetharamu N. · · 2018 · cited 120× · PMID 30249178 · DOI 10.1186/s10020-018-0051-4
Immunotherapy in endometrial cancer: rationale, practice and perspectives.
Cao W, Ma X, Fischer JV, Sun C, et al · · 2021 · cited 79× · PMID 34134781 · DOI 10.1186/s40364-021-00301-z
Biology drives the discovery of bispecific antibodies as innovative therapeutics.
Nie S, Wang Z, Moscoso-Castro M, D'Souza P, et al · · 2020 · cited 79× · PMID 33928225 · DOI 10.1093/abt/tbaa003
Immunotherapy for nasopharyngeal carcinoma: Current status and prospects (Review).
Huang H, Yao Y, Deng X, Huang Z, et al · · 2023 · cited 78× · PMID 37417358 · DOI 10.3892/ijo.2023.5545

Verify or expand the search:

Other trials of XmAb20717

Trials testing the same drug.

NCT05900648 — Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular R · Phase 2 · withdrawn
NCT05337735 — A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers · Phase 2 · suspended
NCT05297903 — XmAb20717 in Advanced Biliary Tract Cancers · Phase 2 · active not recruiting

Other recruiting trials for Melanoma

Currently open trials in the same condition.

NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07224425 — A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it · Phase 1 · recruiting
NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
NCT07225036 — Promoting Immunotherapy Efficacy With Low-Dose Liver RT · NA · recruiting
NCT07379138 — Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for the Improve · NA · recruiting

Other Xencor, Inc. trials

Trials by the same sponsor.

NCT06173505 — Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced N · Phase 1, PHASE2 · terminated
NCT05996445 — A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors · Phase 1 · terminated
NCT05585034 — Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Adva · Phase 1 · completed
NCT06005792 — Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis · Phase 1 · terminated
NCT05032040 — A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03517488 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xencor, Inc.
Last refreshed: 1 December 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03517488.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing